Indira Maisnam discusses the current knowledge of obesity in diabetes and the effects some treatments have on weight management.
1) Why do you think that the effect of pharmacotherapy in obesity for weight loss is just satisfactory and not excellent? (0:12)
2) What are the other options that we may explore? (1:07)
3) How does the adipose tissue work in the homeostasis of body weight? (1:33)
4) Do the treatments that are currently available for diabetes effect adipose tissue? (2:25)
5) What is in the pipeline with regards to adipose tissue? (3:20)
Speaker disclosure: Indira Maisnam has nothing to disclose in relation to this video interview.
Filmed at the European Association for the Study of Diabetes (EASD) annual meeting, Berlin, Germany, 2018
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The Role of Semaglutide in the Treatment Paradigm for Prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs Liraglutide 3.0 mg on Glucose Metabolism – STEP 8 Post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 Agonists and Other Emerging Treatments of Obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!